



Rosemary Gibson
Senior Advisor, Hastings Center

Author, *China Rx: Exposing the Risks of America's Dependence on China for Medicine*

Rosemary Gibson is Senior Advisor at the Hastings Center and Perspectives Editor at JAMA Internal Medicine. She is author of *China Rx: Exposing the Risks of America's Dependence on China for Medicine*. It reveals the dramatic shift in where medicines are made and the implications for U.S. health security and national security.

Ms. Gibson is recipient of the highest honor from the American Medical Writers Association for her outstanding contributions to the public's interest in reporting on critical health care issues. *China Rx* was selected by the National Press Club for its 2018 book fair.

She serves as board chair of the Altarum Institute, a non-profit health systems research group in Ann Arbor. She is a member of the MedStar Institute for Quality and Patient Safety Advisory Board and the board of the Accreditation Council for Graduate Medical Education. She served on the ACGME CLER Evaluation Committee to advance patient safety and quality in teaching hospitals and other clinical learning environments. Ms. Gibson is faculty for the Academy for Emerging Leaders in Patient Safety which hosts summer immersion programs in patient safety for medical students, nursing students, and residents.

At the Robert Wood Johnson Foundation, Ms. Gibson architected its decade-long national strategy to integrate palliative care into the nation's hospitals. The number of palliative care programs in acute care facilities increased from a handful in 1999 to 1,950 in 2018. She is recipient of the Lifetime Achievement Award from the American Academy of Hospice and Palliative Medicine.

Her other books include *Wall of Silence* which puts a human face on the Institute of Medicine report, *To Err is Human*. *Treatment Trap*, *Battle Over Health Care*, and *Medicare Meltdown* chronicle the behind-the-scenes forces that shape health care today.

Questions for the Panelist

- How are Chinese companies integrated into global pharmaceutical and medicine supply chains and what are the implications for U.S. public health regulators and businesses?
- What specific sourcing vulnerabilities exist for U.S. private, public health and military medical facilities, patients, and consumers vis-à-vis Chinese medical and biotech companies? Is the U.S. government adequately equipped to address these vulnerabilities?
- What factors have contributed to China's emergence as a global hub of counterfeit medicines and pharmaceuticals?
- What risks, if any, does greater U.S.-China health cooperation pose for U.S. economic and national security interests?
- The Commission is mandated to make policy recommendations to Congress based on its hearings and other research. What are your recommendations for Congressional action related to the topic of your testimony?